The global obesity-treatment business entered a new phase on 10 August after Britain’s medicines regulator approved Eli Lilly’s Foundayo tablet for weight management and type 2 diabetes.
Foundayo contains orforglipron, an oral medicine that activates the GLP-1 receptor involved in appetite and blood-sugar regulation. Unlike Lilly’s injectable Mounjaro treatment, it is swallowed once daily.
The authorization is Foundayo’s first European approval and makes Britain an important testing ground for Lilly’s international expansion. The company is expected to introduce the medicine through private prescriptions later in August. It is not yet available through Britain’s National Health Service, which requires a separate cost-effectiveness assessment before adopting new treatments.
The approval strengthened investor confidence, pushing Lilly’s shares more than 3% higher following the announcement. Approval and market report
For Lilly, the commercial attraction of an oral treatment extends beyond patients who dislike injections. Tablets can be easier to transport, store and distribute than injectable products, which often require specialised devices and temperature-controlled supply chains.
Foundayo can be taken with or without food and does not require patients to delay eating or drinking after taking it. That convenience may help distinguish it from Novo Nordisk’s oral Wegovy product, which requires specific fasting and water instructions.
The two companies are competing for leadership in one of the pharmaceutical industry’s fastest-growing markets. Injectable GLP-1 treatments have already produced enormous revenues, but supply shortages, production expenses and affordability concerns have restricted access in numerous countries.
Oral products could expand the market by making treatment more acceptable to a broader group of patients. They may also allow pharmaceutical companies to manufacture and distribute larger volumes without depending as heavily on injection pens.
Lilly has not yet announced the final British price. However, Foundayo is expected to cost less than Mounjaro, which can reach approximately £399 per month through private providers. Pricing will strongly influence whether the new product becomes widely accessible or remains concentrated among wealthier customers.
The medicine previously received authorization in the United States. Lilly says it has submitted orforglipron for weight-management or diabetes approval in more than 40 countries, indicating that Britain is intended to become the beginning of a wider international rollout. Lilly’s official product information
Competition will remain intense. Novo Nordisk secured British approval for its Wegovy tablet in June, giving it an earlier position in the UK’s oral obesity-treatment market. Other pharmaceutical companies are also developing medicines designed to provide greater weight reduction, fewer side effects or simpler dosing.
Why This Matters
The business impact extends beyond the two leading manufacturers. A successful transition from injections to tablets could reshape pharmaceutical factories, pharmacy distribution, private telehealth services and public healthcare budgets.
It could also place downward pressure on prices as several companies compete for patients. However, approval does not guarantee broad access. Public health systems must still decide whether the treatment’s benefits justify its cost, while regulators will continue monitoring safety.
For Lilly, the British decision provides a gateway into Europe and another opportunity to challenge Novo Nordisk. For the wider industry, it signals that the next stage of the obesity-drug race may be fought at the pharmacy counter rather than through an injection pen.
